Nephrogenic systemic fibrosis and its impact on abdominal imaging

Area of Science:

• Nephrology
• Radiology
• Toxicology

Background:

• Nephrogenic systemic fibrosis (NSF) is a serious condition linked to gadolinium-based contrast agents (GBCAs).
• Over 300 cases of NSF have been reported, primarily in patients with severe kidney impairment or acute renal failure following GBCA injection.
• High-dose GBCA administration, especially for abdominal magnetic resonance (MR) imaging, is a significant risk factor.

Purpose of the Study:

• To review current knowledge on nephrogenic systemic fibrosis (NSF).
• To outline strategies for preventing NSF in at-risk patients.
• To highlight the impact of recent recommendations on NSF incidence.

Main Methods:

• Literature review of reported NSF cases and risk factors.
• Analysis of the association between GBCA administration and NSF development.
• Evaluation of the effectiveness of current preventative guidelines.

Main Results:

• Major risk factors for NSF include renal insufficiency, prompt dialysis failure post-GBCA, nonionic linear agents, hyperphosphatemia, and younger age.
• Recent recommendations to use GBCAs cautiously in patients with renal impairment have drastically reduced new NSF cases.
• No new NSF cases were reported in 2008-2009, indicating successful implementation of preventative measures.

Conclusions:

• Nephrogenic systemic fibrosis (NSF) has been virtually eliminated through careful GBCA administration in patients with severe or acute renal failure.
• Avoiding high GBCA doses and scheduling MR imaging before dialysis sessions are crucial for preventing NSF in dialysis patients.
• Adherence to updated guidelines ensures patient safety and minimizes the risk of NSF associated with GBCAs.